
Is ABT (Abbott Laboratories) Halal or Haram?
Abbott Laboratories demonstrates strong shariah compliance across all financial metrics, with interest-bearing debt sitting comfortably at 7.6% of its market capitalization, well below the 33% AAOIFI threshold. Furthermore, the company's non-operating interest income is negligible at just 0.52% of total revenue, indicating that its earnings are driven almost entirely by its core healthcare operations rather than impermissible financial activities.
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for ABT
Business Activity
Permissible
Abbott Laboratories passes the business sector screen as its core revenue stems from permissible activities like medical devices, diagnostic systems, branded generic medicines, and nutritional products like Similac and Ensure.
Debt / Market Cap
7.58%
Interest Income
0.52%
Cash & Securities
4.50%
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified global healthcare giant known for a wide array of life-saving technologies and products, ranging from the FreeStyle Libre glucose monitoring system to nutritional staples like Ensure and Similac. The company operates across four main segments: medical devices, diagnostics, nutritional products, and established pharmaceuticals, making it a critical player in both hospital settings and consumer healthcare shelves worldwide.
For Muslim investors seeking ethical and compliant opportunities, Abbott Laboratories is currently classified as Halal, having passed all four rigorous AAOIFI screening criteria . The company's business activities are inherently permissible, focusing on health and well-being rather than prohibited industries like alcohol , gambling, or conventional finance, providing a solid foundation for a shariah-compliant portfolio.
Financially, Abbott maintains a very clean balance sheet from an Islamic perspective, with interest-bearing debt accounting for only 7.6% of its market cap, significantly lower than the 33% limit allowed by scholars. Additionally, its cash and interest-bearing securities make up just 4.5% of its market value, and interest income is a minor 0.5 2% of revenue, suggesting the company is not heavily reliant on generating income from impermissible cash deposits.
Investors should continue to monitor Abbott's acquisition strategy, as large healthcare mergers can sometimes alter debt ratios rapidly. However, at present , Abbott represents a stable, defensive stock option that aligns well with Islamic investing principles due to its low leverage and clearly permissible revenue streams.
CEO
Robert Ford
Employees
114,000
IPO Date
1980-03-17
Headquarters
North Chicago, IL, US
Website
www.abbott.comABT Key Financial Statistics
Revenue
$44.33B
Net Income
$6.52B
EPS (Diluted)
$3.72
Stock Price
114.17
Beta
0.75
52-Week Range
105.27-141.23
Total Debt
$15.07B
Total Equity
$52.13B
Current Ratio
1.58
ABT Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+5.7%
Prior year: $41.95B
Net Debt
$6.54B
Cash: $8.52B — Debt: $15.07B
R&D Spending
$2.96B
% of Revenue
6.7%
Frequently Asked Questions About ABT
Is ABT (Abbott Laboratories) stock halal to invest in?▾
What does Abbott Laboratories do?▾
What screening criteria were used for ABT?▾
Does ABT require income purification?▾
When was ABT last screened?▾
Disclaimer
This shariah compliance assessment for ABT (Abbott Laboratories) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-02-24.